Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label dose-escalation and expansion study of BGB-16673 in Chinese patients with B-cell malignancies
CTR20220399Phase 2Active
- Sponsor
- BeiGene
- Start
- May 2022
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of catadegbrutinib in B-cell malignancy, marginal zone B-cell lymphoma (MZL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by BeiGene. Started May 2022; status: active.
02
Drugs
catadegbrutinib
03
Conditions
B-cell malignancymarginal zone B-cell lymphoma (MZL)follicular lymphoma (FL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20220399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220399.